Pediatric Acute Leukemia: Diagnosis and Management
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 590
Special Issue Editor
Special Issue Information
Dear Colleagues,
Acute leukemia (AL) is the most prevalent cancer in childhood, accounting for about 30% of all malignancies in people under 20 years of age. In the last few decades, remarkable progress has been made in the outcome of pediatric AL, with a survival rate of up to 90% for acute lymphoblastic leukemia (ALL) and 70% for acute myeloid leukemia (AML) in selected patient cohorts. Outcome improvements rely on an increased proficiency in chemotherapy management and stem cell transplantation, the ability to control opportunistic infections, an ever-greater knowledge of risk-related biological features of ALLs and AMLs, and progressive amelioration in evaluating response to therapy by minimal residual disease (MRD) assessment. Regardless, pediatric ALs still relapse in a significant proportion of patients and are associated with a severe outcome. Therefore, it is mandatory to improve the precocious identification of high-risk AML and ALL subtypes and address them to a more intense therapeutic regimen including immunotherapy and targeted therapy.
We welcome the submission of original research and review articles focusing on innovation in pediatric ALL and AML new diagnosis and relapse, MRD monitoring during therapy, and their management.
Prof. Dr. Barbara Buldini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pediatric acute leukemia
- acute lymphoblastic leukemia
- acute myeloid leukemia
- diagnosis
- immunophenotype
- measurable residual disease
- target therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
